Compare HCAT & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HCAT | MOLN |
|---|---|---|
| Founded | 2008 | 2004 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 121.7M | 144.0M |
| IPO Year | 2019 | 2021 |
| Metric | HCAT | MOLN |
|---|---|---|
| Price | $1.04 | $4.10 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 10 | 2 |
| Target Price | $2.53 | ★ $8.38 |
| AVG Volume (30 Days) | ★ 764.1K | 3.6K |
| Earning Date | 05-06-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $311,136,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $318.52 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1.48 | N/A |
| 52 Week Low | $1.04 | $3.36 |
| 52 Week High | $5.06 | $5.36 |
| Indicator | HCAT | MOLN |
|---|---|---|
| Relative Strength Index (RSI) | 30.06 | 40.81 |
| Support Level | N/A | $3.53 |
| Resistance Level | $2.41 | $4.51 |
| Average True Range (ATR) | 0.10 | 0.17 |
| MACD | 0.01 | -0.04 |
| Stochastic Oscillator | 0.00 | 29.63 |
Health Catalyst Inc provides data and analytics technology and services to healthcare organizations. It has two operating segments. The Technology segment, the key revenue driver, includes data platforms, analytics applications, and support services. This generates revenues mainly from contracts that are cloud-based subscription arrangements, time-based license arrangements, and maintenance and support fees; the Professional Services segment is generally the combination of analytics, implementation, strategic advisory, outsourcing, and improvement services to deliver expertise to its customers to more fully configure and utilize the benefits of the technology offerings.
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.